ImmunoGen announces IMGN901 clinical data presented at ASH

ImmunoGen announced the presentation of new clinical data with the company's targeted anticancer compound, IMGN901. The data were from a Phase I clinical study assessing IMGN901 used in combination with lenalidomide and dexamethasone to treat patients with CD56-expressing relapsed or relapsed/refractory multiple myeloma. The data were reported in an oral presentation at the 54th American Society of Hematology, or ASH, Annual Meeting and Exposition in Atlanta, Georgia.


View Comments (0)

Recommended for You